Novo Nordisk oral semaglutide shows superior glycemic control in teens

DENMARK—Novo Nordisk has reported positive topline results from its phase 3a PIONEER TEENS trial, which evaluated oral semaglutide for treating type 2 diabetes in children and adolescents aged 10 to 17 years.

The study showed that oral semaglutide achieved a significantly greater reduction in HbA1c levels, a key marker of blood sugar control, compared to placebo.

In addition, the treatment demonstrated a safety profile consistent with earlier semaglutide trials, reinforcing its tolerability in younger populations.

Oral semaglutide is already marketed as Rybelsus® in both the European Union and the United States.

The company also plans to introduce it in pill form under the Ozempic® brand in the US, expanding access to non-injectable treatment options.

Addressing a growing clinical need
Martin Holst Lange, executive vice president and chief scientific officer at Novo Nordisk, emphasized the urgency of expanding treatment options for younger patients.

He noted that the prevalence of type 2 diabetes in children and adolescents has risen sharply over the past two decades.

Despite this trend, available therapies remain limited, highlighting a significant unmet medical need.

He further explained that oral semaglutide has already demonstrated strong glycaemic control and a well-established safety profile in adults with type 2 diabetes.

Moreover, it has shown cardiovascular benefits, which are particularly important given the long-term risks associated with the disease.

According to Lange, the PIONEER TEENS results confirm that oral semaglutide can effectively support glycaemic control in younger patients who require more than standard treatment options.

Challenges in current treatment approaches

Type 2 diabetes in children and adolescents is both severe and progressive, often leading to higher risks of early mortality in adulthood.

However, current management strategies remain limited.

Existing guidelines recommend metformin and insulin as first-line therapies.

While metformin is widely used, it fails to achieve adequate glycaemic control in nearly half of adolescent patients.

On the other hand, insulin therapy often leads to complications such as hypoglycaemia and weight gain, making it less ideal for long-term use in this age group.

Globally, the burden of youth-onset type 2 diabetes continues to rise.

In 2021, an estimated 14.6 million adolescents were living with the condition, and projections indicate this number could reach 20.9 million by 2030.

These figures underline the growing demand for more effective and patient-friendly treatment options.

Potential first-in-class oral therapy

Notably, the PIONEER TEENS trial represents the first clinical study of an oral GLP-1 receptor agonist in this age group.

Pending regulatory approvals, oral semaglutide could become the first and only oral GLP-1 therapy to demonstrate superior glycaemic efficacy compared to placebo in children and adolescents, while maintaining a safety profile consistent with previous semaglutide treatments.